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1  | BACKGROUND
The COVID-19 pandemic presents health policymakers and clini-
cians with difficult decisions under conditions of uncertainty, facing 
an infection that in its early stages mimics many other influenza-like 
illnesses (ILIs).1 The range of diagnostic tests available for SARS-
CoV-2 is growing, but they have important limitations. RT-PCR is the 
reference standard but depends on advanced laboratory facilities 
that are not available in primary care or community settings, and long 
turn-around times for results increase the risk of nosocomial trans-
mission.2 Performance profiles for RT-PCR tests for SARS-CoV-2 are 
also sub-optimal, with reported false-negative rates of up to 30%.3
Point-of-care tests (POCTs) could transform epidemic control 
by better guiding triage decisions to reduce risks of nosocomial and 
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Abstract
Point-of-care tests (POCTs) offer considerable potential for improving clinical and 
public health management of COVID-19 by providing timely information to guide 
decision-making, but data on real-world performance are in short supply. Besides 
SARS-CoV-2-specific tests, there is growing interest in the role of surrogate (non-
specific) tests such as FebriDx, a biochemical POCT which can be used to distinguish 
viral from bacterial infection in patients with influenza-like illnesses. This short report 
assesses what is currently known about FebriDx performance across settings and 
populations by comparison with some of the more intensively evaluated SARS-CoV-
2-specific POCTs. While FebriDx shows some potential in supporting triage for early-
stage infection in acute care settings, this is dependent on SARS-CoV-2 being the 
most likely cause for influenza-like illnesses, with reduction in discriminatory power 
when COVID-19 case numbers are low, and when co-circulating viral respiratory 
infections become more prevalent during the autumn and winter. Too little is cur-
rently known about its performance in primary care and the community to support 
use in these contexts, and further evaluation is needed. Reliable SARS CoV2-specific 
POCTs—when they become available—are likely to rapidly overtake surrogates as the 
preferred option given the greater specificity they provide.
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community transmission. However, reliable POCT options in the pe-
riod before a detectable antibody response has been mounted are few. 
There could therefore be a role for surrogate tests (those that do not 
directly diagnose SARS-CoV-2) for screening. These include FebriDx, a 
low-cost POCT used to distinguish bacterial from viral infections and 
originally designed to support rational antibiotic prescribing.4 A num-
ber of evaluations are ongoing to consider the value of FebriDx in acute 
and primary care settings during the COVID-19 pandemic.5,6
This short report explores the place of surrogate POCTs in the 
diagnostic mix in high-income settings, by considering the perfor-
mance of FebriDx and SARS-CoV-2-specific POCTs on the market.
2  | POC T MODALITIES AND SARS- CoV-2 
IN THEORY
There are four POC testing approaches for SARS-CoV-2 with differ-
ent decision-making implications: 
• Class I: POCTs for the presence of SARS-CoV-2 antigens to iden-
tify active infection.7
• Class II: molecular POCTs to identify active infection but with 
shorter turn-around times than conventional RT-PCR.
• Class III: serological antibody tests (IgG and/or IgM) for confirma-
tion of infection. This includes most SARS-CoV-2-specific POCTs.
• Class IV: surrogate tests (including FebriDx) that do not directly 
diagnose SARS-CoV-2 but can be used as screening tests.
Point-of-care test utility varies according to time from symptom 
onset. PCR-based tests offer better sensitivity in the first few days, 
but performance declines from as early as day 5.8 Class III POCTs 
likely offer value only from day 7 to 8 because of the time taken 
to generate a detectable antibody response.9-11 All POCTs are, for 
now, used to guide interim decision-making pending final diagnosis 
via RT-PCR.
While class I, II and III modalities test for SARS-CoV-2-specific 
antigens, RNA or antibodies respectively, FebriDx is a composite 
tool that detects both myxovirus resistance protein A (MxA—ele-
vated in acute viral infections) and C-reactive protein (CRP—elevated 
in either viral or bacterial infections). The test uses fixed thresholds 
for “positive” MxA and CRP levels; any positive MxA result, with or 
without positive CRP, indicates viral infection.4 These markers are 
used because: (a) CRP production is stimulated by interleukin-6 (IL-
6), produced in higher quantities in bacterial infections; (b) MxA ex-
pression is exclusively driven by type 1 interferons (IFN-1), secreted 
in response to detection of viral signatures by host intracellular re-
ceptors. IFN-1 and consequently MxA are thought to be specific to 
viral infection.4
There may be grounds for caution in interpreting FebriDx results 
at the extremes of the clinical course. Early SARS-CoV infection 
appears not to activate MxA and IFN-1 transcription in the normal 
way,12 and if SARS-CoV-2 similarly attenuates early MxA expres-
sion, FebriDx may have low sensitivity in at least the first few days 
following infection. The low MxA threshold for a positive result 
(40 ng/mL) means FebriDx may nevertheless be positive even with 
weak MxA activation.
3  | COMPAR ATIVE PERFORMANCE OF 
SURROGATE AND SPECIFIC TESTS FOR 
SARS- CoV-2
The key risk in using any POCT is of a false-negative result leading 
to inappropriate management of SARS-CoV-2 infection. For FebriDx, 
an additional risk is that a positive result cannot exclude the possibil-
ity of another virus as the cause of infection.
Studies evaluating FebriDx mostly consider performance in dis-
tinguishing viral from bacterial causes of acute respiratory illnesses 
in toto, in secondary care. Reported sensitivities range from 64% 
to 90%, and specificities from 78% to 88%.13-16 However, two re-
cent studies from the UK evaluate FebriDx specifically for screening 
for SARS-CoV-2 in hospital: a small-scale pilot,5 and a study nested 
within a non-randomised clinical trial of molecular POCTs.6 These 
studies report impressive sensitivities and specificities of 100% and 
93%, and 100% and 86%, respectively. However, interpretation 
is limited by (a) the use of clinical diagnosis as reference standard 
rather than RT-PCR in the first study, (b) evaluation in single sec-
ondary care centres in England in both cases and (c) the inclusion 
of patients in the range 2-7 days from symptom onset only in the 
first study. Finally, test performance in both studies may have been 
artificially boosted because they were conducted at times when the 
range of co-circulating respiratory viruses was lower than in the au-
tumn and winter.
A comprehensive assessment of POCT field performance is be-
yond the scope of this paper, and available data indicate large con-
text-dependent variations even for the same platform. However, 
based on data covering the first 14 days from symptom onset col-
lated by FIND,17 SARS CoV2-specific tests perform comparably to 
FebriDx (Figure 1). Caveats to this assessment are that: (a) the ma-
jority of tests are antibody-based and therefore only reactive some 
time after symptom onset, and (b) most studies used patient samples 
collected in clinical settings only. Evidence on the performance of 
FebriDx or any other POCT for diagnosis of SARS-CoV-2 infection 
in key workers, care home residents or other high-risk populations is 
in very short supply.
4  | IMPLIC ATIONS FOR APPLIC ATIONS OF 
FEBRIDX
What can be said about the utility of FebriDx by comparison with 
other POCTs given the limited available data? Preliminary judge-
ments are possible depending on the (a) timing and location of test-
ing, and (b) the broader epidemiological context.
FebriDx offers greatest value early in the clinical course, given 
the absence of reliable antigen POCTs and scarcity of molecular 
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POCTs. However, reported sensitivity ranges for COVID and non-
COVID patients in healthcare settings are wide.5,6,13-16 The test 
should therefore be positioned within a diagnostic algorithm, along-
side other clinical and radiological markers, to optimise performance. 
FebriDx may have a role in triage in the community where access to 
advanced diagnostics is limited, but there are no performance data 
for the test in this context, and only a handful of studies evaluate any 
SARS-CoV-2 POCTs in the community.2
Secondly, surrogate tests such as FebriDx will likely only have 
value around the peak of the epidemic curve, in a situation where 
widespread community transmission is probable. Here, a positive 
result in a patient with an ILI could be interpreted as indicative of 
COVID-19 pending laboratory confirmation. Discriminatory power 
will likely decline during the autumn and winter months where 
other viral diagnoses are equally or more likely. Here, the clinical 
and social cost of imposing infection control measures such as iso-
lation on the basis of a presumptive diagnosis alone may become 
unjustifiable.
5  | CONCLUSION
Although a growing number of specific and surrogate POCTs are now 
available for SARS-CoV-2, test performance is variable across the clin-
ical course. Given existing data, its ease of use and low cost, FebriDx 
shows promise as a screening tool for early-stage COVID-19 infection 
in hospital settings. However, not enough is yet known about its value 
in primary care or community settings. Reliable, SARS CoV2-specific 
tests—when they become available—are likely to be the preferred 
option especially during the autumn and winter months when the in-
cidence of other, co-circulating respiratory viral infections will affect 
the discriminating power of surrogate tests like FebriDx.
CONFLIC T OF INTERE S T
All authors declare that they have no conflicts of interest in relation 
to this work.
AUTHOR CONTRIBUTIONS
Sharif A. Ismail: Conceptualization (equal); investigation (equal); 
writing – original draft (lead); writing – review and editing (equal). 
Catherine Huntley: Investigation (equal); writing – review and edit-
ing (equal). Nathan Post: Investigation (equal); writing – review and 
editing (equal). Samuel Rigby: Investigation (equal); writing – review 
and editing (equal). Madhumita Shrotri: Investigation (equal); writ-
ing – review and editing (equal). Sarah V. Williams: Investigation 
(equal); writing – review and editing (equal). Sharon J. Peacock: 
Conceptualization (equal); writing – review and editing (equal).
ORCID
Sharif A. Ismail  https://orcid.org/0000-0001-7246-7337 
R E FE R E N C E S
 1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortal-
ity of adult inpatients with COVID-19 in Wuhan, China: a retrospec-
tive cohort study. Lancet. 2020;395(10229):1054-1062.
 2. Döhla M, Boesecke C, Schulte B, et al. Rapid point-of-care testing 
for SARS-CoV-2 in a community screening setting shows low sensi-
tivity. Public Health. 2020;182:170-172.
F I G U R E  1   Scatter plot of sensitivity 
and specificity values for antigen- and 
antibody-based POCTs, molecular rapid 
diagnostic tests and scores for FebriDx 
from the two studies that specifically 
evaluate performance in screening for 
COVID-19 published thus far. Bubble 
sizes indicate the size of the population 
involved in each study; the centre point 
of each bubble gives the sensitivity 
and specificity point estimate [Source: 
FIND Dx open-source data on test 
performance17
6  |     ISMAIL et AL.
 3. Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, et al. 
False-negative results of initial RT-PCR assays for COVID-19: a sys-
tematic review. medRxiv. 2020 (ref 2020.04.16.20066787).
 4. NICE. FebriDx for C-reactive protein and Myxovirus virus resistance 
protein A testing in primary care: A testing in primary care Medtech 
innovation briefing. London, UK: NICE; 2017.
 5. Karim N, Ashraf MZ, Naeem M, et al. Utility of FebriDx in early 
identification of possible COVID19 infection. Res Sq. 2020;1-12. 
https://doi.org/10.21203 /rs.3.rs-25802 /v1
 6. Clark TW, Brendish NJ, Poole S, et al. Diagnostic accuracy of the 
FebriDx host response point-of-care test in patients hospitalised 
with suspected COVID-19. J Infect. 2020. S0163-4453(20)30432-1. 
https://doi.org/10.1016/j.jinf.2020.06.051
 7. Cheng MP, Papenburg J, Desjardins M, et al. Diagnostic testing for 
severe acute respiratory syndrome-related coronavirus-2: a narra-
tive review. Ann Intern Med. 2020;13:13.
 8. Wölfel R, Corman VM, Guggemos W, et al. Virological as-
sessment of hospitalized patients with COVID-2019. Nature. 
2020;581:465-469.
 9. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-
CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 
2020;28. ciaa344. https://doi.org/10.1093/cid/ciaa344
 10. Guo L, Ren L, Yang S, et al. Profiling early humoral response to 
diagnose novel coronavirus disease (COVID-19). Clin Infect Dis. 
2020;71(15):778-785.
 11. Huang AT, Garcia-Carreras B, Hitchings MDT, et al. A system-
atic review of antibody mediated immunity to coronaviruses: 
antibody kinetics, correlates of protection, and association of 
antibody responses with severity of disease. medRxiv. 2020 (ref 
2020.04.14.20065771).
 12. Spiegel M, Weber F. Inhibition of cytokine gene expression and in-
duction of chemokine genes in non-lymphatic cells infected with 
SARS coronavirus. Virol J. 2006;29(3):17.
 13. Beard K, Chan C, Mills S, Poole S, Brendish N, Tristan WC. Evaluation of 
the febridx host response point-of-care test to differentiate viral from 
bacterial etiology in adults hospitalized with acute respiratory illness 
during influenza season. Open Forum Infect Dis. 2019;6(Suppl 2):2019.
 14. Sambursky R, Shapiro N. Evaluation of a combined MxA and CRP 
point-of-care immunoassay to identify viral and/or bacterial im-
mune response in patients with acute febrile respiratory infection. 
Eur Clin Respir J. 2015;2(1):28245.
 15. Self W, Rosen J, Sharp S, et al. Diagnostic accuracy of FebriDx: a 
rapid test to detect immune responses to viral and bacterial upper 
respiratory infections. J Clin Med. 2017;6(10):94.
 16. Shapiro NI, Self WH, Rosen J, et al. A prospective, multi-centre US 
clinical trial to determine accuracy of FebriDx point-of-care testing 
for acute upper respiratory infections with and without a confirmed 
fever. Ann Med. 2018;50(5):420-429.
 17. FIND. SARS-CoV2 diagnostics: performance data. 2020. https://
www.finddx.org/covid -19/dx-data/. Accessed June 02, 2020.
How to cite this article: Ismail SA, Huntley C, Post N, et al. 
Horses for courses? Assessing the potential value of a 
surrogate, point-of-care test for SARS-CoV-2 epidemic control. 
Influenza Other Respi Viruses. 2021;15:3–6. https://doi.
org/10.1111/irv.12796
